Roche ratchets up Alzheimer's work in growing neuroscience pipeline

Luca Santarelli, Roche's head of neuroscience

Roche ($RHHBY), known as the world's largest provider of cancer drugs, wants to be a leading player in therapies for Alzheimer's disease specifically and neuroscience more broadly. As Roche neuroscience head Luca Santarelli tells Pharmalot, the Swiss drug giant now has about a dozen clinical-stage programs in his group, and the pipeline is growing. With gantenerumab, the company is focusing on patients who start showing signs of Alzheimer's before dementia sets in. The focus on treating patients at an early stage is the name of the game for Roche's top Alzheimer's program. Q&A

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.